Clinical versus pathologic stage I and II Hodgkin's disease.
During an 11-year period, 76 patients with pathologic stage (PS) and 69 with clinical stage (CS) I and II Hodgkin's disease were irradiated. The PS and CS patients were comparable by sex, age, stage, and histopathologic types. Treatment group 1 received a mantle of I and II A lymphocyte predominant and nodular sclerosis plus paraaortic for I-II A mixed cellular and lymphocyte-depleted or B symptoms; group 2 received mantle plus paraaortic for I-II A lymphocyte predominant and nodular sclerosis, and total nodal irradiation for the unfavorable group. The disease-free survival is 47% for the PS and 64% for CS patients in group 1. For group 2, 85% of PS and 83% of CS patients are disease free. Analysis of infradiaphragmatic failures fails to show any advantage for PS over CS. Laparotomy does not obviate infradiaphragmatic irradiation for stage I and II Hodgkin's disease.
D000293:Adolescent; D000328:Adult; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006689:Hodgkin Disease / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D007813:Laparotomy; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011859:Radiography; D012189:Retrospective Studies; D013156:Splenectomy